NCT05469048 (NEPTUNE) is a clinical trial in Sepsis, sponsored by Immunexpress.

Who is sponsoring NCT05469048?

NCT05469048 is sponsored by Immunexpress.

What condition does NCT05469048 study?

NCT05469048 studies Sepsis, Systemic Inflammatory Response Syndrome.

Is NCT05469048 still recruiting?

NCT05469048 is currently completed. Last updated 2 October 2024.

Last reviewed 2024-10-02 · How we verify

NCT05469048: NEPTUNE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Near Patient Molecular Testing in Sepsis

Completed Last updated 2 October 2024

What this trial tests

trial in Sepsis in 63 participants. Completed in 31 October 2022.

Timeline

12 March 2020

Primary endpoint
31 May 2021

31 October 2022

Quick facts

Lead sponsor	Immunexpress
Status	Completed
Study type	OBSERVATIONAL
Enrollment	63
Start date	12 March 2020
Primary completion	31 May 2021
Estimated completion	31 October 2022
Sites	3 locations across United States

Conditions studied

Sepsis — all drugs for Sepsis →
Systemic Inflammatory Response Syndrome — all drugs for Systemic Inflammatory Response Syndrome →

Sponsor

Immunexpress

Who can join

Adults 18 to 95, any sex, with Sepsis or Systemic Inflammatory Response Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation.
Balk R, Esper AM, Martin GS, Miller RR, et al · · 2024 · cited 24× · PMID 38592057 · DOI 10.3390/jcm13051194
The Role of Transcriptomics in Redefining Critical Illness.
Pelaia TM, Shojaei M, McLean AS. · · 2023 · cited 19× · PMID 36941625 · DOI 10.1186/s13054-023-04364-2

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05469048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunexpress
Last refreshed: 2 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05469048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing